Alexander Eggermont is an internationally recognized expert in surgical oncology, immunotherapy, melanoma, sarcoma and cancer drug development. He currently holds roles as Chief Scientific Officer at the Princess Máxima Center for Pediatric Oncology & Professor of Immunotherapy at the University Medical Center Utrecht, the Netherlands; Professor of Oncology (Classe Exceptionnelle) at Paris-Saclay University, France; Coordinator, Comprehensive Cancer Center Program for Deutsche KrebsHilfe; and Strategic Advisor at the German Cancer Consortium (DKFZ). Prof. Eggermont was previously Director General of Gustave Roussy Comprehensive Cancer Center, Villejuif, France (2010-2019) and Professor of Oncology (Classe Exceptionnelle) at Paris-Saclay University (2012-2020), France; Professor of Surgical Oncology (2003-2016) and Endowed Professor of International Networking in Cancer Research (2011-2018) at Erasmus University MC, Rotterdam, the Netherlands. He holds a PhD in tumor immunology from Erasmus University and is Fellow of the National Institutes of Health’s National Cancer Institute (NIH-NCI, Stever Rosenberg Lab, Surgery Branch). Prof. Eggermont has served as President of ECCO, President of the EORTC, was a member of the Board of Directors of ASCO, served on the Editorial Board of the Journal of Clinical Oncology, and is currently Editor-in-Chief of the European Journal of Cancer. Prof. Eggermont has published more than 1,000 peer-reviewed papers and his expertise has been acknowledged by many professional awards throughout his career.
William L. Redmond is a Member (Full Professor) and Director of the Immune Monitoring Laboratory at the Earle A. Chiles Research Institute (EACRI) at the Providence Cancer Institute. Dr. Redmond’s research seeks to elucidate the mechanisms by which immunotherapies including OX40 agonists, common gamma chain cytokines (e.g., IL-2, IL-15), and checkpoint blockade synergize with novel therapies, such as galectin-3 inhibitors, radiation therapy, and tumor vaccines to augment anti-tumor immunity. Furthermore, he seeks to identify biomarkers of response to treatment that may provide insight into the mechanisms by which immunotherapy improves outcomes in patients with advanced malignancies. Dr. Redmond has extensive experience with murine tumor models and, as Director of the EACRI Immune Monitoring Laboratory, oversees translational research efforts seeking to develop and implement state-of-the-art immune profiling assays for the evaluation of anti-tumor immunity in cancer patients. This includes analysis of peripheral blood, serum, and tumor tissue by multi-parameter flow cytometry and multiplex immunohistochemistry. Dr. Redmond expertise in tumor immunology has led to numerous peer-reviewed publications and grant support from agencies including the NIH, Susan G. Komen, Prostate Cancer Foundation, American Cancer Society, and V Foundation.
Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.